Krishnan Krish S sold $862K of KRYS
Krishnan Krish S (President and CEO) sold 2,784 shares of Krystal Biotech, Inc. (KRYS) at $309.49 ($0.86M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a sentiment datapoint but does not, by itself, change fundamentals or introduce a new catalyst for KRYS.
Market read
Traders may briefly reassess sentiment around KRYS due to insider selling, but 10b5-1 framing suggests limited informational content.
What to watch
Insider sales can be routine; traders should check whether there are concurrent insider buys/sales patterns or changes in option exercises/awards not captured by this single transaction.
Background
This is an SEC Form 4 insider transaction: CEO/President/10% owner sold 2,784 shares at ~$309.49/share on 2026-06-04 under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Krystal Biotech CEO/President Krishnan Krish S sold $862K of KRYS shares via an open-market transaction under a 10b5-1 plan.
Low near-term impact; any reaction is likely limited and quickly absorbed given 10b5-1 pre-arrangement.
The filing is a routine insider transaction with stated 10b5-1 pre-arranged plan, reducing interpretability as a new fundamental signal.
Market effects
Minimal; single-company insider sale without accompanying operational/regulatory/drug-trial catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.
Key entities
- issuerKrystal Biotech, Inc.
Subject of the SEC Form 4 insider sale by its President and CEO.
- insiderKrishnan Krish S
President and CEO; sold $861,620.44 of KRYS shares under a 10b5-1 plan.
